Centers for Disease Control and Prevention.. HIV surveillance report, 2015; vol. 27. Available at: www.cdc.gov/hiv/library/reports/hiv-surveillance.html Accessed December18, 2016.
2.
Centers for Disease Control and Prevention.. HIV surveillance report, 2014; vol. 26. Available at: www.cdc.gov/hiv/library/reports/surveillance Accessed January28, 2016.
3.
US Public Health Service.. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: A clinical practice guideline. 2014. Available at: www.cdc.gov/hiv/pdf/prepguidelines2014.pdf Accessed December21, 2016.
4.
DonnelD, BaetenJM, BumpusNN, et al.HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr, 2014; 66:340–348.
5.
CotrellML, YangKH, PrinceHMA, et al.A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis, 2016; 214:55–64.
6.
CottrellML, SrinivasN, KashubaAD. Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol, 2015; 11:893–905.
7.
CelumCL, Delany-MoretlweS, McConnelM, et al.Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc, 2015; 18(Suppl 3):20227.
8.
GliddenDV, AmicoKR, LiuAY, et al.Symptoms, side effects and adherence in the iPrEx open-label extension. Clin Infect Dis, 2016; 62:1172–1177.
9.
ShethAN, RolleCP, GandhiM. HIV pre-exposure prophylaxis for women. J Virus Erad, 2016; 2:149–155.
10.
Truvada [Package Insert].. Gilead Sciences, Foster City, CA; April 2016. Available at: www.gilead.com/pdf/truvada_pi.pdf Accessed December18, 2016.
